New combo therapy shows promise for untreatable liver cancer
NCT ID NCT07610551
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a combination of three treatments—radioactive beads (SIRT-Y90), an immunotherapy drug (atezolizumab), and a drug that cuts off tumor blood supply (bevacizumab)—for people with advanced liver cancer that cannot be surgically removed. Researchers will track how well the tumors shrink and how long patients live, using data from about 50 participants across eight hospitals in China. The goal is to see if this triple approach is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SIRT-Y90 (radioactive beads), atezolizumab (immunotherapy), bevacizumab (anti-angiogenic drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced liver cancer that cannot be removed by surgery, potentially shrinking tumors and extending life.
What could go wrong
This is a small, early-stage study with only 50 participants, so results may not apply to everyone. Combining these treatments may also increase side effects like liver damage or bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
No. 777, Xitai Road, Chang'an District, Xi'an City, Shaanxi Province, China
RECRUITINGXi’an, Shanxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••